Overview

The National Cancer Center Japan (Tokyo) and Otsuka Pharmaceutical Co., Ltd. (Tokyo) have jointly developed a comprehensive genomic profiling assay for hematologic malignancies.

This assay covers almost all categories of hematologic malignancies: myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm; lymphoid malignancies such as acute lymphoblastic leukemia, lymphoma, and myeloma; and congenital bone marrow failure syndromes. This assay will provide a valuable information for clinicians and patients in diagnosis, treatment, and prognostic prediction.

In the future, in order to facilitate the development of personalized medicine for blood cancers, the performance of this assay will be assessed at National Cancer Center Japan, Kyushu University (Fukuoka), Kyoto University (Kyoto), and Nagoya Medical Center (Aichi). Its feasibility and clinical utility will also be investigated at National Cancer Center Japan in a prospective clinical trial.

In this research project, Otsuka Pharmaceutical and major facilities in Japan will form a joint research consortium and work together.